Liraglutide in India: the one GLP-1 with real cheaper options
Liraglutide is the once-daily injectable GLP-1 behind Saxenda (weight loss) and Victoza (diabetes). Unlike semaglutide and tirzepatide, liraglutide's patent has ended in several markets and Indian companies have launched non-originator versions, so a cheaper, regulator-checked option genuinely exists. But two honest catches remain: the Indian non-originator products are approved for diabetes, not weight loss, and you still need a doctor's prescription and a licensed pharmacy, because a 'biosimilar' or 'generic' is not identical to the originator and the fake online market is real.
If you have heard that a cheaper Indian 'generic' of a GLP-1 weight-loss injection exists, the molecule people are talking about is usually liraglutide. This is the one GLP-1 where that story is partly true, and this guide gives you the honest picture. Liraglutide is the active medicine in Saxenda (the weight-loss brand) and Victoza (the diabetes brand). Its patent has ended in several markets, and Indian companies have launched or received approval for non-originator liraglutide products. So unlike semaglutide and tirzepatide, which are still under patent, liraglutide genuinely has regulator-checked cheaper options in India. But there are two honest catches you must know. First, the Indian non-originator liraglutide products approved so far are for type 2 diabetes, not for weight loss, so they are not a cheap substitute for Saxenda. Second, even for diabetes, you still need a doctor's prescription and a licensed pharmacy, because a 'biosimilar' or 'generic' is not identical to the originator, quality matters, and the fake online liraglutide market is real. Please talk to your doctor before any decision about these medicines.
The baseline: what liraglutide is, what it does, and the India landscape
Liraglutide is a once-daily subcutaneous injection (a small injection under the skin) that works as a GLP-1 receptor agonist. The originator company is Novo Nordisk. The same molecule is sold as two different brands at two different strengths. Saxenda is the weight-loss brand, and the DailyMed label for Saxenda lists it as a 'glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term'. Victoza is the diabetes brand, used for type 2 diabetes. The big study that proved liraglutide works for weight loss is the SCALE trial, published in the New England Journal of Medicine in 2015. It found that '3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control', with a mean loss of 8.4 kg on liraglutide versus 2.8 kg on placebo at 56 weeks, roughly an 8 percent weight loss. This is real and meaningful, though less than what semaglutide and tirzepatide achieve. The common side effects, straight from the Saxenda label, are nausea (39.3 percent), vomiting (15.7 percent) and diarrhoea (20.9 percent), which are dose-dependent and usually get better if the dose is increased slowly. The label also warns about gallbladder events and, rarely, pancreatitis, and carries a boxed warning about thyroid C-cell tumours seen in rats and mice. Now the India part. Liraglutide's patent has expired in several markets, and Indian companies have moved in. Glenmark launched a biosimilar of liraglutide under the brand name Lirafit in January 2024, after approval from the Drug Controller General of India, 'indicated for improving glycemic control in adult patients with type 2 diabetes mellitus'. Biocon received approval from the Central Drugs Standard Control Organisation in June 2025 for its generic liraglutide, 'the generic version of Novo Nordisk's Victoza', as '6 mg/ml solution for injection in pre-filled pen and cartridge', also 'indicated for the treatment of insufficiently controlled Type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above'. Both are for diabetes, not for the Saxenda weight-loss indication. This is the honest starting point: liraglutide is the one GLP-1 where India has real, regulator-checked non-originator options, but so far those options are for the diabetes use, and they still require a prescription.
Indian 'generic liraglutide' is the same as Saxenda for cheap, and liraglutide generics mean semaglutide generics too.
VerdictTwo halves, both wrong. First half: a biosimilar or generic is not identical to the originator. It is a separate, regulator-checked product that must be shown to be similar, but quality and monitoring still matter, and the World Health Organization warns you to still use a prescription and a licensed pharmacy and to avoid unusually low prices. Second, and more important, the Indian non-originator liraglutide products approved so far are for type 2 diabetes, not for the Saxenda weight-loss indication. Glenmark's Lirafit is 'indicated for improving glycemic control in adult patients with type 2 diabetes mellitus', and Biocon's generic liraglutide is 'indicated for the treatment of insufficiently controlled Type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above'. Neither is a cheap swap for Saxenda. Using a diabetes-indication liraglutide off-label for weight loss on your own is not the same as being prescribed Saxenda, and that decision belongs to your doctor. Second half of the claim: false. Liraglutide's patent has ended in several markets, which is why Indian non-originator versions exist. Semaglutide and tirzepatide are still under patent, so true generics of those do not exist in the standard sense. Cheap 'semaglutide' sold online is usually compounded or, worse, falsified. So liraglutide is the exception, not the rule.
Stay safe and honest with liraglutide in India
- See your doctor first. Liraglutide is a prescription injectable. The dose, the need, and the brand must come from a doctor who knows your health, not from an online ad. If you want it for weight loss, that is a different medical decision from diabetes treatment.
- Know the indication. The Indian non-originator liraglutide products approved so far are for type 2 diabetes, not for the Saxenda weight-loss indication. Do not treat a diabetes product as a cheap do-it-yourself weight-loss pen. Let your doctor decide what is right for you.
- Buy only from a licensed pharmacy, with a valid prescription. The World Health Organization says to always buy from authorized or licensed pharmacies and to be wary of unusually low prices and injectable GLP-1 stored outside the refrigerator.
- Understand that a biosimilar or generic is not identical to the originator. It is a separate, regulator-checked product, but quality and monitoring still matter. Ask your doctor or pharmacist about the specific product you are given.
- Titrate slowly for nausea. Nausea, vomiting and diarrhoea are common and dose-dependent. Follow your doctor's titration schedule, and report side effects that do not settle.
- Watch the cold chain. Liraglutide pens must be stored and shipped at the right temperature. A seller who cannot show proper storage may be handing you a spoiled or fake product.
- Avoid online and informal sellers. The World Health Organization warns that unmet GLP-1 demand is being filled with falsified injections that may have no active ingredient, may contain a wrong substitute such as insulin, or may be non-sterile, and that this can be life-threatening when injected.
- Report any side effect or suspected fake to your doctor and to the pharmacist. In India you can also report adverse drug reactions through the national pharmacovigilance programme.
The bottom line
Liraglutide is the one GLP-1 where India genuinely has cheaper, regulator-checked non-originator options, because its patent has ended in several markets, unlike semaglutide and tirzepatide which are still under patent. Glenmark's Lirafit and Biocon's generic liraglutide are real, approved products, and they lower the cost of therapy by roughly 70 percent. But two honest catches stand. First, the Indian non-originator products approved so far are for type 2 diabetes, not for the Saxenda weight-loss indication, so they are not a cheap do-it-yourself swap for Saxenda. Second, a biosimilar or generic is not identical to the originator, and the fake online liraglutide market is real, which the World Health Organization has warned can be life-threatening when injected. So the safe, honest path is the same simple one: talk to your doctor, take a prescription, and buy only from a licensed pharmacy. Burnie can help you log your food and see your daily calorie deficit, but medicine decisions belong with your doctor, not an online deal.